Account Info
Log Out
English
Back
Log in to access Online Inquiry
Back to the Top

NEWS

Zevra Therapeutics’ MIPLYFFA™ (arimoclomol) Receives U.S. FDA Approval as Treatment for Niemann-Pick Disease Type C
Zevra Therapeutics announced FDA approval of MIPLYFFA™ (arimoclomol) as the first treatment for Niemann-Pick disease type C (NPC), an ultra-rare neurodegenerative disease. MIPLYFFA is indicated for use with miglustat to treat neurological manifestations in patients 2 years and older. The approval is based on a 12-month trial showing MIPLYFFA halted disease progression. Zevra received a rare pediatric disease priority review voucher and launched AmplifyAssist™, a patient support program.

MIPLYFFA will be commercially available in 8-12 weeks. The drug is administered orally three times daily, with dosage ranging from 47-124 mg based on body weight. Zevra estimates 900 people in the U.S. have NPC, with about one-third diagnosed. The approval marks a significant milestone for NPC patients, offering the first FDA-approved treatment option for this progressive and fatal disease.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only. Read more
2
1
+0
Translate
Report
3392 Views
Comment
Sign in to post a comment
    Spread kindness and love. Life is short. Don’t let greed eat you.
    2359Followers
    106Following
    25KVisitors
    Follow